As of today (2023-12-04), Biogen's current share price is €213.60. Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was €72.62. Biogen's Cyclically Adjusted PB Ratio for today is 2.94.
The historical rank and industry rank for Biogen's Cyclically Adjusted PB Ratio or its related term are showing as below:
HAM:IDP'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.92 Med: 7.57 Max: 16.44
Current: 3.06
During the past years, Biogen's highest Cyclically Adjusted PB Ratio was 16.44. The lowest was 2.92. And the median was 7.57.
HAM:IDP's Cyclically Adjusted PB Ratio is ranked worse than 65.33% of 724
companies
in the Drug Manufacturers industry
Industry Median: 2.01
vs HAM:IDP: 3.06
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Biogen's adjusted book value per share data for the three months ended in Sep. 2023 was €93.660. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €72.62 for the trailing ten years ended in Sep. 2023.
Shiller PE for Stocks: The True Measure of Stock Valuation
Biogen Cyclically Adjusted PB Ratio Historical Data
The historical data trend for Biogen's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Biogen Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Cyclically Adjusted PB Ratio
7.16
6.21
4.62
3.93
3.96
Biogen Quarterly Data
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Cyclically Adjusted PB Ratio
3.89
3.96
3.83
3.81
3.35
Competitive Comparison
For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen Cyclically Adjusted PB Ratio Distribution
For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Biogen's Cyclically Adjusted PB Ratio falls into.
Biogen Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Biogen's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Biogen (HAM:IDP) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Biogen Cyclically Adjusted PB Ratio Related Terms
Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
213.6 
(1.23%) Dec. 01
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
HAM:IDP has been successfully added to your 